The KIAA1217 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T lymphoblast cell line, designed to disrupt the KIAA1217 gene. This polyclonal pool contains a heterogeneous mixture of cells harboring independent CRISPR/Cas9-mediated gene disruptions at the KIAA1217 locus, providing a loss-of-function model for investigating the uncharacterized role of KIAA1217 in T-cell biology.
The Jurkat E6-1 cell line, originally established from the peripheral blood of a 14-year-old male with acute T-cell leukemia, is a widely utilized model for T-cell receptor (TCR) signaling, interleukin-2 (IL-2) production, and apoptosis. Jurkat cells exhibit constitutive TCR-CD3 complex expression and rapidly activate downstream signaling cascades upon stimulation, making them ideal for dissecting molecular mechanisms governing T-cell activation and leukemogenesis. They have been instrumental in HIV research due to their permissiveness to viral replication and TCR-dependent HIV-1 LTR transactivation.
The KIAA1217 gene product remains poorly characterized, with current knowledge limited to its potential involvement in cell proliferation and migration processes. No upstream regulators, downstream targets, or interacting protein partners have been definitively established, and the gene??s position within known signal transduction cascades is undetermined. Consequently, the molecular mechanisms through which KIAA1217 may affect cellular functions such as proliferation, survival, or motility in T-lymphoid cells are not yet understood. Disruption of KIAA1217 in Jurkat polyclonal cells offers a valuable tool to dissect these unknown functions by enabling comparative phenotypic analyses.
In the context of Jurkat T lymphoblasts, loss of KIAA1217 function may provide insights into its contribution to T-cell leukemia biology, given the cell line??s origin from acute T-cell leukemia. Genetic alterations in KIAA1217 have been sporadically observed in cancer genomic studies, hinting at a possible role in oncogenesis, though this remains speculative. By employing this knockout model, researchers can investigate whether KIAA1217 disruption affects TCR signaling, IL-2 production, or apoptotic responses, thereby clarifying its functional relevance in T-cell pathophysiology. Such studies are essential to decipher whether KIAA1217 acts as a tumor suppressor or oncogene in lymphoid malignancies.
Typical applications of the KIAA1217 Knockout Jurkat Polyclonal Cells include functional genomics studies to characterize the gene??s role in T-cell leukemia, proliferation, and apoptosis. The polyclonal population is well-suited for downstream assays such as Western blotting to confirm KIAA1217 protein loss, RT-qPCR to quantify gene expression changes, flow cytometry to assess apoptosis and cell cycle distribution, MTT-based proliferation assays, and migration/invasion assays to evaluate cellular motility. This model facilitates high-throughput screening for phenotype discovery and can be integrated into co-culture systems or drug response studies to explore KIAA1217-dependent pathways. Researchers may also combine this knockout tool with phospho-flow cytometry or gene expression profiling to uncover signaling networks indirectly affected by KIAA1217 disruption. For further technical details or customization options, please contact Ascent Research.
